S. Cytryn

Common Germline Mutations in a Patient With Multiple Primary Lung Cancers.

A. Moreira, A. Chachoua, J. Sabari, 2019, Clinical lung cancer.

Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.

A. Chachoua, J. Sabari, P. Boland, 2021, Lung cancer.

Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis

A. Pavlick, P. Boland, T. Niewold, 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant

M. Abdul-Hay, S. Cytryn, 2020, Clinical hematology international.

Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure

L. Medeiros, Shaoying Li, A. Behdad, 2020, Cancer.

HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers.

Y. Janjigian, S. Cytryn, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases

M. Suarez‐Almazor, A. Pavlick, M. Krogsgaard, 2023, Oncoimmunology.

658 Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases

M. Suarez‐Almazor, A. Pavlick, J. Weber, 2020, Journal for ImmunoTherapy of Cancer.

P2.04-48 Use of Immune Checkpoint Inhibitors in Patients with Advanced Lung Cancer and Pre-Existing Autoimmune Diseases

V. Velcheti, S. Sandigursky, S. Cytryn, 2019, Journal of Thoracic Oncology.

Toxicities of single agent and combination immune checkpoint inhibitors in patients with autoimmune diseases.

S. Sandigursky, S. Cytryn, E. Efuni, 2019, Journal of Clinical Oncology.

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.

M. Berger, Laura H. Tang, D. Solit, 2023, The Lancet. Oncology.